Valuation: Shanghai Shyndec Pharmaceutical Co., Ltd.

Capitalization	14.52B 2.02B 1.75B 1.64B 1.49B 2.75B 174B 3.11B 19.19B 7.47B 79.73B 7.59B 7.43B 291B	P/E ratio 2025 *	12x	P/E ratio 2026 *	10.7x
Enterprise value	14.52B 2.02B 1.75B 1.64B 1.49B 2.75B 174B 3.11B 19.19B 7.47B 79.73B 7.59B 7.43B 291B	EV / Sales 2025 *	1.21x	EV / Sales 2026 *	1.15x
Free-Float	41.74%	Yield 2025 *	2.07%	Yield 2026 *	2.33%

More valuation ratios * Estimated data

Chart: Shanghai Shyndec Pharmaceutical Co., Ltd.

Timeframe

Style

Dynamic Chart

Latest news: Shanghai Shyndec Pharmaceutical Co., Ltd.

Shyndec Pharmaceutical's Two Drugs Pass Regulatory Evaluation	06-05	MT
Shyndec Pharma Gets Registration Certificate for Hypertension Drug	06-05	MT
Shanghai Shyndec Pharmaceutical Gets Approval for Anti-Tumor Injection	05-29	MT
Shyndec Pharmaceutical Unit's Amikacin Sulfate Injection Passes Regulatory Consistency Evaluation	05-14	MT
Shanghai Shyndec Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2025	04-28	CI
Shyndec Pharmaceutical Passes Consistency Evaluation for Antibiotic Drug	04-16	MT
Shanghai Shyndec Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2024	03-27	CI
Shyndec Pharmaceutical Subsidiary Passes Generic Drug Consistency Evaluation for Asthma Drug	03-18	MT
Shyndec Pharmaceutical's Unit Gets Registration Certificate for Methylprednisolone Tablets	03-17	MT
Shyndec Pharmaceutical Obtains Registration Certificates for Antiviral, Anticoagulant Drugs	03-10	MT
Shanghai Shyndec Pharmaceutical's Pravastatin Sodium Tablets Passes Chinese Drug Regulator's Consistency Evaluation	03-03	MT
Shyndec Pharma's Units Get Three Drug Registration Certificates	01-22	MT
Shanghai Shyndec's Shenzhen Unit Passes EU GMP Inspection	01-20	MT

More news

Managers and Directors: Shanghai Shyndec Pharmaceutical Co., Ltd.

Manager	Title	Age	Since
Jing Zu DFI	Director of Finance/CFO	55	-
Qian Yin Jing IRC	Investor Relations Contact	45	2019-09-12
Zhong Xi Zhang SEC	Corporate Secretary	49	2024-03-27

Director	Title	Age	Since
Xiang Dong Yu BRD	Director/Board Member	61	2019-01-30
Peng Wang BRD	Director/Board Member	43	2022-11-27
Yong Liu BRD	Director/Board Member	56	2021-05-16

More insiders

Specialty & Advanced Pharmaceuticals

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD.	-1.55%	+0.74%	-1.37%	+19.40%	2.06B
MERCK KGAA	-1.42%	-0.35%	-33.37%	-31.50%	58.6B
KYOWA KIRIN CO., LTD.	0.00%	+0.99%	-7.56%	-15.32%	9.07B
HALOZYME THERAPEUTICS, INC.	-0.89%	-0.33%	+8.97%	+25.45%	6.72B
YUHAN CORPORATION	-1.75%	+2.60%	+43.34%	+105.27%	5.96B
SK BIOPHARMACEUTICALS CO., LTD.	-3.42%	-0.11%	+13.16%	+11.48%	5.4B
BETTA PHARMACEUTICALS CO., LTD.	-1.97%	+2.13%	+65.40%	+24.96%	3.79B
SUPERNUS PHARMACEUTICALS, INC.	-0.87%	-1.75%	+22.63%	+22.86%	1.83B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD.	-3.26%	-7.06%	-62.78%	-7.65%	1.82B
INDIVIOR PLC	+0.49%	+0.99%	-19.61%	-27.66%	1.73B
Average	-1.44%	-0.57%	+2.88%	+12.73%	9.7B
Weighted average by Cap.	-1.27%	+0.37%	-15.43%	-10.41%

See all sector performances

SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD. is a China-based company principally engaged in the research and development, production and sales of pharmaceutical products. The Company's main products are antibiotics, circulatory system drugs and biological products, including garlic oil soft capsules, lecithin soft capsules and deep-sea fish oil soft capsules. Its bulk pharmaceutical chemicals (BPCs) include macrolide antibiotics, antiviral, anti-tumor, cardiovascular, hormones and weight loss drugs. The Company also offers topical preparations, such as gynecological suppositories and dermatology preparations.

Employees

11,472

Sector

Pharmaceuticals

Calendar

08-26 - Q2 2025 Earnings Release (Projected)

More about the company

Quotes

Date	Price	Change	Volume
25-06-12	10.83 ¥	-1.55%	13,878,800
25-06-12	11.00 ¥	+0.09%	9,855,107
25-06-11	10.99 ¥	-0.09%	8,769,204
25-06-10	11.00 ¥	+0.18%	15,651,310
25-06-09	10.98 ¥	+2.14%	21,096,350

End-of-day quote Shanghai S.E., June 12, 2025

More quotes

Income Statement and Estimates

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

10.83

Average target price

Consensus

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Select your edition

All financial news and data tailored to specific country editions

NORTH AMERICA

United-States

Canada

End-of-day quote Shanghai S.E. Other stock markets 2025-06-13			5-day change	1st Jan Change
10.83 ^CNY	-1.55%		+0.74%	-9.30%

1 day	-1.55%
1 week	+0.74%
Current month	+0.74%
1 month	+4.84%
3 months	-4.24%
6 months	-14.66%
Current year	-9.30%

1 week	10.64	11.05
1 month	10.29	11.05
Current year	9.69	12.01
1 year	9.69	14.41
3 years	7.61	14.41
5 years	7.61	14.41
10 years	7.61	28.54

	2025 *	2026 *
Net sales	12.04B 1.68B 1.45B 1.36B 1.23B 2.28B 144B 2.58B 15.91B 6.19B 66.09B 6.29B 6.16B 241B	12.64B 1.76B 1.52B 1.43B 1.3B 2.39B 152B 2.7B 16.7B 6.5B 69.39B 6.61B 6.47B 253B
Net income	1.2B 167M 145M 136M 123M 227M 14.41B 257M 1.59B 618M 6.6B 628M 615M 24.1B	1.35B 188M 163M 153M 138M 256M 16.2B 289M 1.79B 695M 7.42B 706M 691M 27.09B
Net Debt	-	-

Shanghai Shyndec Pharmaceutical Co., Ltd. Stock

Equities

600420

CNE000001JG2